Deep proteome analysis of time-series human plasma samples applied to Covid-19 antibody test

For the purpose of Covid-19 antibody testing, the human plasma samples acquired over a period of 310 days from August 18, 2021, to June 22, 2022, were subjected to DIA LC-MS proteome analysis. This process led to the acquisition of a quantitative protein profile and allowed for the validation of the temporal behavior of expressed proteins within the samples. A total of 1502 proteins were identified from the plasma samples. Before vaccination, after the first dose, after the second dose, and during the period after contracting the novel coronavirus, protein quantification values during each event interval were compared. Despite minimal changes observed before and after Covid-19 vaccination, notable proteins exhibiting distinct high-expression and low-expression patterns were identified after contracting the novel coronavirus infection.

[1]  J. Vallon-Christersson,et al.  Choice of High-Throughput Proteomics Method Affects Data Integration with Transcriptomics and the Potential Use in Biomarker Discovery , 2022, Cancers.

[2]  D. Shi,et al.  Up-regulated 60S ribosomal protein L18 in PEDV N protein-induced S-phase arrested host cells promotes viral replication , 2022, Virus Research.

[3]  W. Zeng,et al.  Identification of Novel Therapeutic Candidates Against SARS-CoV-2 Infections: An Application of RNA Sequencing Toward mRNA Based Nanotherapeutics , 2022, Frontiers in Microbiology.

[4]  Guo Ci Teo,et al.  dia-PASEF data analysis using FragPipe and DIA-NN for deep proteomics of low sample amounts , 2022, Nature Communications.

[5]  A. Kohl,et al.  Recent insights into SARS‐CoV‐2 omicron variant , 2022, Reviews in medical virology.

[6]  Ruibing Chen,et al.  A data-independent acquisition (DIA)-based quantification workflow for proteome analysis of 5000 cells. , 2022, Journal of pharmaceutical and biomedical analysis.

[7]  J. Kublin,et al.  COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective , 2022, Open forum infectious diseases.

[8]  Yizhao Luan,et al.  Deficiency of ribosomal proteins reshapes the transcriptional and translational landscape in human cells , 2022, Nucleic acids research.

[9]  A. Kaneda,et al.  Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant , 2022, Nature.

[10]  Xiaoli An,et al.  Loss of RPS27a expression regulates the cell cycle, apoptosis, and proliferation via the RPL11-MDM2-p53 pathway in lung adenocarcinoma cells , 2022, Journal of experimental & clinical cancer research : CR.

[11]  A. Droit,et al.  DIA proteomics data from a UPS1-spiked E.coli protein mixture processed with six software tools , 2022, Data in brief.

[12]  K. Tsumoto,et al.  Proteomic identification and validation of novel interactions of the putative tumor suppressor PRELP with membrane proteins including IGFI-R and p75NTR , 2021, The Journal of biological chemistry.

[13]  Xue Cai,et al.  Data‐Independent Acquisition Mass Spectrometry‐Based Proteomics and Software Tools: A Glimpse in 2020 , 2020, Proteomics.

[14]  Christoph B. Messner,et al.  DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput , 2019, Nature Methods.

[15]  K. Tsumoto,et al.  Development of drug discovery screening system by molecular interaction kinetics-mass spectrometry. , 2018, Rapid communications in mass spectrometry : RCM.

[16]  N. Kenmochi,et al.  Cross talk between TP53 and c-Myc in the pathophysiology of Diamond-Blackfan anemia: Evidence from RPL11-deficient in vivo and in vitro models. , 2018, Biochemical and biophysical research communications.

[17]  H. Tojo,et al.  A selected reaction monitoring mass spectrometric assessment of biomarker candidates diagnosing large-cell neuroendocrine lung carcinoma by the scaling method using endogenous references , 2017, PloS one.

[18]  M. Frilander,et al.  Evolutionarily conserved exon definition interactions with U11 snRNP mediate alternative splicing regulation on U11–48K and U11/U12–65K genes , 2015, RNA biology.

[19]  T. Kodama,et al.  An improvement on mass spectrometry-based epigenetic analysis of large histone-derived peptides by using the Ionization Variable Unit interface. , 2015, Analytical biochemistry.

[20]  M. Phelps,et al.  Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[21]  H. Tojo,et al.  Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma. , 2010, Journal of proteomics.

[22]  H. Tojo,et al.  Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. , 2010, Journal of proteomics.

[23]  J. W. Davis,et al.  The ribosomal protein rpL11 associates with and inhibits the transcriptional activity of peroxisome proliferator-activated receptor-alpha. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[24]  Henning Urlaub,et al.  The human 18S U11/U12 snRNP contains a set of novel proteins not found in the U2-dependent spliceosome. , 2004, RNA.

[25]  C. Will,et al.  Identification of both shared and distinct proteins in the major and minor spliceosomes. , 1999, Science.

[26]  R. Padgett,et al.  Requirement of U12 snRNA for in Vivo Splicing of a Minor Class of Eukaryotic Nuclear Pre-mRNA Introns , 1996, Science.

[27]  R. Pearson,et al.  Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. , 2016, Cancer discovery.